title: Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs.
abstract: OBJECTIVE
  To study the potential side effects and toxicity of inhaling prostacyclin (PGI2) aerosol for 8 h.
  
  
  METHODS
  In a prospective, randomized study 14 healthy lambs received either PGI2 (n = 7) or 0.9% NaCl (n = 7) as an aerosol for 8 h.
  
  
  METHODS
  Institute for Surgical Research of the Ludwig-Maximilians-University of Munich.
  
  
  METHODS
  All animals were studied under general anesthesia in a prone position. They were first intubated endotracheally and later tracheotomized. PGI2 solution (median dose 28 ng/kg per min) or 0.9% NaCl was administered with a jet nebulizer (delivery rate 4-10 ml/h; mass median diameter of aerosol particles 3.1 microns). Bronchoalveolar lavage was performed before and after the inhalation period to collect epithelial lining fluid of alveoli.
  
  
  RESULTS
  Hemodynamic and respiratory parameters, systemic resorption (plasma levels of 6-keto-prostaglandin-F 1 alpha), in vitro bleeding time, collagen-induced platelet aggregation and global biochemical and cellular composition of the epithelial lining fluid were examined in order to assess the side effects and signs of acute pulmonary toxicity induced by inhaled PGI2. No statistically significant differences were found between the PGI2 and the control groups for any of the parameters examined.
  
  
  CONCLUSIONS
  Inhalation of PGI2 (28 ng/kg per min) over a period of 8 h in healthy lambs does not produce major side effects or acute pulmonary toxicity.
authors.affiliation: Institute for Surgical Research, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Habler
authors.forename: M
authors.initials: M
authors.lastname: Kleen
authors.forename: B
authors.initials: B
authors.lastname: Zwissler
authors.forename: R
authors.initials: R
authors.lastname: Pusch
authors.forename: M
authors.initials: M
authors.lastname: Welte
authors.forename: C
authors.initials: C
authors.lastname: Vogelmeier
authors.forename: B
authors.initials: B
authors.lastname: Kempter
authors.forename: F
authors.initials: F
authors.lastname: Krombach
authors.forename: K
authors.initials: K
authors.lastname: Messmer
mesh_terms: D000208:Acute Disease; D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D000831:Animals, Newborn; D001992:Bronchoalveolar Lavage Fluid; D004353:Drug Evaluation, Preclinical; D016903:Drug Monitoring; D011464:Epoprostenol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D008171:Lung Diseases / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D011897:Random Allocation; D012756:Sheep; D013997:Time Factors
chemical_list: D000336:Aerosols; D011464:Epoprostenol